Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

No toxicity seen for antimalarial candidate
July 2017
SHARING OPTIONS:

WASHINGTON, D.C.—A recently published article from 60 Pharmaceuticals LLC detailed results from a study that found that super-therapeutic doses of tafenoquine, an investigational antimalarial agent, appear not to result in neurologic toxicity in adult rats. The results were published in Travel Medicine and Infectious Disease. The study sought to determine the maximum tolerated dose and neurobehavioral effects of tafenoquine, and measured a number of biological markers—including blood, motor activity and central nervous system changes—after the drug was administered at levels much higher than what would be used to treat humans. No histopathological changes were found in the brain at doses up to the minimum lethal single dose in adult rats.
 
“We are committed to improving the health and lives of people around the world through developing products that can help treat and prevent tropical diseases,” said Dr. Geoffrey Dow, CEO of 60 Pharmaceuticals.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.